X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (78) 78
index medicus (73) 73
hematology (69) 69
male (64) 64
middle aged (63) 63
female (61) 61
adult (56) 56
transplantation (47) 47
aged (40) 40
transplantation, homologous (31) 31
oncology (30) 30
stem cells (28) 28
hematopoietic stem cells (27) 27
retrospective studies (25) 25
leukemia (24) 24
immunology (23) 23
analysis (22) 22
treatment outcome (22) 22
disease-free survival (21) 21
hematology, oncology and palliative medicine (21) 21
adolescent (20) 20
hematopoietic stem cell transplantation (20) 20
recurrence (20) 20
stem cell transplantation (19) 19
leukemia, myeloid, acute - therapy (17) 17
bone-marrow-transplantation (16) 16
leukemia, myeloid, acute - mortality (16) 16
therapy (16) 16
hematopoietic stem cell transplantation - adverse effects (15) 15
risk (15) 15
survival analysis (15) 15
young adult (15) 15
survival (14) 14
versus-host-disease (14) 14
cancer (13) 13
chemotherapy (13) 13
hematopoietic stem cell transplantation - methods (13) 13
risk factors (13) 13
transplantation conditioning - methods (13) 13
acute myeloid leukemia (12) 12
acute myeloid-leukemia (12) 12
leukemia, myeloid, acute - genetics (12) 12
prognosis (12) 12
mortality (11) 11
myelodysplastic syndrome (11) 11
allogeneic transplantation (10) 10
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
blood (10) 10
bone marrow (10) 10
leukemia, lymphocytic, chronic, b-cell - therapy (10) 10
stem-cell transplantation (10) 10
survival rate (10) 10
alemtuzumab (9) 9
care and treatment (9) 9
patients (9) 9
prospective studies (9) 9
unrelated donors (9) 9
adults (8) 8
allogeneic stem cell transplantation (8) 8
aml (8) 8
chronic lymphocytic-leukemia (8) 8
leukemia, myeloid, acute - immunology (8) 8
patient outcomes (8) 8
remission induction (8) 8
t cells (8) 8
time factors (8) 8
transmission (8) 8
transplantation conditioning (8) 8
acute disease (7) 7
bone-marrow (7) 7
climate change mitigation technologies in information andcommunication technologies [ict], i.e. information andcommunication technologies aiming at the reduction of thir ownenergy use (7) 7
diagnosis (7) 7
electric communication technique (7) 7
electricity (7) 7
general tagging of cross-sectional technologies spanning over several sections of the ipc (7) 7
general tagging of new technological developments (7) 7
graft vs host disease - prevention & control (7) 7
hematopoietic stem cell transplantation - mortality (7) 7
immunotherapy (7) 7
impact (7) 7
leukemia, lymphocytic, chronic, b-cell - mortality (7) 7
myelodysplastic syndromes - therapy (7) 7
relapse (7) 7
research (7) 7
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (7) 7
technologies or applications for mitigation or adaptation againstclimate change (7) 7
telephonic communication (7) 7
tissue donors (7) 7
wireless communications networks (7) 7
abridged index medicus (6) 6
child (6) 6
chronic lymphatic leukemia (6) 6
chronic lymphocytic leukemia (6) 6
fludarabine (6) 6
follow-up (6) 6
kaplan-meier estimate (6) 6
leukemia, myeloid, acute - drug therapy (6) 6
leukemia, myeloid, acute - pathology (6) 6
marrow-transplantation (6) 6
medical research (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1691 - 1699
Summary Background Preclinical data and results from non-randomised trials suggest that the multikinase inhibitor sorafenib might be an effective drug for the... 
Hematology, Oncology and Palliative Medicine | AML | ONCOLOGY | ACUTE MYELOGENOUS LEUKEMIA | BONE-MARROW | CLASSIFICATION | FLT3 MUTATIONS | CYTARABINE | STEM-CELL TRANSPLANTATION | COMBINATION | ELDERLY-PATIENTS | CHEMOTHERAPY | Niacinamide - analogs & derivatives | Recurrence | Age Factors | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Transplantation, Homologous | Neoadjuvant Therapy - mortality | Time Factors | Phenylurea Compounds - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Chemotherapy, Adjuvant | Daunorubicin - therapeutic use | Double-Blind Method | Risk Factors | Kaplan-Meier Estimate | Niacinamide - adverse effects | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Disease Progression | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Leukemia, Myeloid, Acute - diagnosis | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - adverse effects | Protein Kinase Inhibitors - therapeutic use | Germany | Antimitotic agents | Clinical trials | Chemotherapy | Antineoplastic agents | Standards | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 6, pp. 768 - 778
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 10, pp. 1035 - 1044
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2018, Volume 36, Issue 19, pp. 1973 - 1980
PurposeVenetoclax is an orally bioavailable B-cell lymphoma 2 inhibitor. US Food and Drug Administration and European Medicines Agency approval for patients... 
MULTICENTER | OPEN-LABEL | ONCOLOGY | BCL-2 INHIBITOR
Journal Article
Journal of Cancer Research and Clinical Oncology, ISSN 0171-5216, 09/2019
Journal Article
The Lancet Oncology, ISSN 1470-2045, 12/2018, Volume 19, Issue 12, pp. 1668 - 1679
Journal Article
Journal Article
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2018, Volume 13, Issue 12, p. e0204290
Journal Article
Journal Article
Haematologica, ISSN 0390-6078, 05/2012, Volume 97, Issue 5, pp. 723 - 730
Background According to WHO 2008 guidelines, the required percentage of cells manifesting dysplasia in the bone marrow to qualify as significant is 10% or over... 
Bone marrow donors | Significant | Dysplasia | Cut off | Hematopoiesis | Percentage | bone marrow donors | REFRACTORY CYTOPENIA | MINIMAL DIAGNOSTIC-CRITERIA |